NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 89 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q4 2013. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2016 | $14,711,000 | +220.6% | 15,575,946 | +351.5% | 89.51% | +31.9% |
| Q4 2015 | $4,588,000 | -84.2% | 3,449,969 | -72.8% | 67.86% | -27.1% |
| Q3 2015 | $28,970,000 | +47.6% | 12,706,324 | +4.2% | 93.08% | +8.0% |
| Q2 2015 | $19,630,000 | +7.8% | 12,192,327 | +6.4% | 86.22% | -8.5% |
| Q1 2015 | $18,213,000 | -34.0% | 11,454,831 | -21.6% | 94.21% | +59.2% |
| Q4 2014 | $27,601,000 | +39.0% | 14,603,603 | -2.9% | 59.19% | +1200.0% |
| Q3 2014 | $19,861,000 | -10.0% | 15,046,431 | +0.9% | 4.55% | +45.4% |
| Q2 2014 | $22,075,000 | -15.2% | 14,915,631 | +6.0% | 3.13% | -74.5% |
| Q1 2014 | $26,036,000 | +92.2% | 14,073,431 | +35.6% | 12.30% | -37.8% |
| Q4 2013 | $13,549,000 | -45.4% | 10,375,329 | +10.8% | 19.76% | +48.2% |
| Q3 2013 | $24,807,000 | +1.1% | 9,361,276 | +1.8% | 13.33% | +54.4% |
| Q2 2013 | $24,549,000 | – | 9,194,517 | – | 8.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 10,375,329 | $13,549,000 | 19.76% |
| Catalyst Capital Advisors LLC | 790,000 | $1,635,000 | 0.53% |
| DSC Advisors, L.P. | 500,000 | $1,035,000 | 0.50% |
| STONERIDGE INVESTMENT PARTNERS LLC | 142,528 | $295,000 | 0.06% |
| Hudock, Inc. | 30,500 | $63,000 | 0.05% |
| BRR OpCo, LLC | 52,700 | $109,000 | 0.05% |
| TFS CAPITAL LLC | 418,074 | $865,000 | 0.04% |
| LifePlan Financial Group, Inc | 28,810 | $60,000 | 0.04% |
| NOMURA HOLDINGS INC | 3,831,177 | $7,947,000 | 0.04% |
| BOLTON LP | 77,400 | $160,000 | 0.03% |